. Cancer cell lines exhibit similar ligand capture differences compared to 12Z. a) HB-EGF release is metalloproteinase dependent. Saturating levels of recombinant EGF (100 ng/mL) were used to stimulate accumulation of HB-EGF in three cell lines, which was blocked with addition of 10 μM BB94 5 min prior to stimulation (n=2), plotted as change in concentration from control-treated cultures. b) The fraction of bulk free ligand was experimentally measured by taking the ratio of supernatant ligand concentrations after 24 h with or without the EGFR blocking antibody, mAb225 in a panel of cancer cell lines (each point denotes an individual cancer cell line; n=2 reps). As seen with 12Z (and in agreement with the computational model), the high affinity ligands HB-EGF and TGFα were captured at higher levels compared to the low-affinity ligand AREG. c) Corresponding to data in b, supernatant ligands were measured in cancer cell lines in the presence of either BB94 or mAb225. Stacked bars correspond to individual cancer cell lines, presented as a fraction of the summed control values. Results show the mAb225 treatment significantly increases supernatant accumulation of the high-affinity ligands HB-EGF and TGFα, to a greater degree than AREG (n=2 ± SEM). [GFP]
[ Figure S8 . Validation of ADAM12 siRNA-mediated knockdown.
a-b) Western blot (a) shows ADAM12-targeted siRNA decreases ADAM12 in whole cell lysate, quantified in b. n.s. denotes nonspecific band. *n≥3 ± SEM; *p<0.05, two-tailed student's t-test. Table S1 . Reaction parameters for the computational model of autocrine signaling. Parameters references with "see methods" were experimentally measured in this work (n≥2 ± SEM), otherwise they were sourced from previously published reports. 
